Just a year ago, Sarepta Therapeutics, Inc. (NASDAQ: SRPT), then known as AVI BioPharma, was a small, little-known developmental stage biopharmaceutical company. It had an undistinguished 32-year history, characterized by year after year of red ink and no marketable product. At the end of last June, the money-losing enterprise had only $16.1 million in working capital, a stock that was trading at 63 cents a share, and a market capitalization of $85 million.
So much has happened since then beyond the cosmetic adoption of a new name. This includes a relocation of operations, changes in executive leadership, and a substantial fortification of the balance sheet. Perhaps most significant, the biotech now sports a market capitalization that's north of $1...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|